Effects of Hyperbaric Oxygen Therapy of Disease Development of (NZBxNZW)F1 Lupus-like Mice

• Main Authors: Hsu-Hsiao-Ping, 徐曉萍
• Other Authors: 陳紹原
• Format: Others
• Language: zh-TW
• Published: 2002
• Online Access: http://ndltd.ncl.edu.tw/handle/98970960672857229467

碩士 === 國防醫學院 === 海底醫學研究所 === 90 === Abstract Hyperbaric oxygen (HBO2) has been widely applied as an adjunctive treatment for a variety of medical disorders, such as carbon monoxide poisoning, decompression sickness, air embolism, chronic osteomyelitis, and burn injuries. The principal known mechanisms of HBO2 are that it increases oxygen concentration in the blood supply, changes the blood flow to the abnormal area, increases the flexibility of red cells, and reduces tissue edema. The effects of HBO2 on the immune system are controversial. Recent studies showed that HBO2 exposure produced changes in the immune system, including lymphocyte redistribution and decreased lymphocyte proliferation. The suppressive function of HBO2 on the immune system might be suggested to be applicable for the treatment of certain autoimmune diseases and allograft rejection problems. System lupus erythematosus (SLE) is a chronic autoimmune disease that generally affects young women. It is characterized by large numbers of autoreactive lymphocytes reacting to self-antigens. The resulting formation of immune complexes can deposit in tissue and activate the complement cascade. Eventually inflammation causes various forms of tissue damage. Murine SLE, which provides a good model of human SLE, has been used to study the pathogenesis of this disease. In this study we used the (NZBxNZW) F1 mice, the unique lupus prone hybrid, to evaluate the effects of HBO2 therapy on autoimmune diseases. The mice were divided into 4 groups. 3 groups of mice were treated with HBO2 at 2.5 ATA for 90 min daily over 2 weeks starting from different age of 3-month-old, 6-month-old, 8-month-old, respectively: A (mice given HBO2 protocol at 3-, 6-, and 8-months-old); B (mice given HBO2 protocol at 6- and 8-months-old); C (mice given HBO2 protocol at 8-month-old); D (control group).Our results show that: (1) HBO2 decreases the percentage of positive proteinuria (>2+) in groups A and B and increases their survival rate; (2) HBO2 reduces the anti-dsDNA IgG antibodies titer in groups A and B; (3) HBO2 changes the distribution of lymphocytes in groups A and B (the percentage of CD3+ [T lymphocyte] is decreased, the CD19+ [B lymphocyte] is increased, the subset of T lymphocytes [CD4+] is decreased); (4) groups A and B have less anti-dsDNA IgG immuno-complex deposition and less brightness in the glomerulus. HBO2 improves the disease expression of (NZBxNZW) F1 in groups A and B mice given the HBO2 protocol at early (3-month-old) and middle (6-month-old) stages of lupus development. Group C mice given the HBO2 protocol at the late stage (8-month-old) of disease development showed no significant beneficial effect.